SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31-February 2 and February 13-16, 2023.
Capstan will participate in the private company exhibition taking place between January 31-February 2, 2023.
About Capstan (www.capstantx.com)
Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.
